Clinical Trial Update: Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment [Phase 1]

View source ↗

Summary

Phase 1 study of pazopanib hydrochloride in pediatric patients with relapsed or treatment-refractory solid tumors has completed, reporting on safety and prelimi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Central Nerv System Germinoma
• Childhood Central Nervous System Choriocarcinoma
• Childhood Central Nervous System Embryonal Tumor
• Childhood Central Nervous System Germ Cell Tumor
• Childhood Central Nervous System Mixed Germ Cell Tumor
• Childhood Central Nervous System Teratoma
• Childhood Central Nervous System Yolk Sac Tumor
• Childhood Soft Tissue Sarcoma

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor | Phase 1 | Status: COMPLETED